Heart Failure and Diabetes Special IssueClinical ResearchMineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes: Data From the MIRAD Trial
Clinical Research
Under an Elsevier user license
open archive
Central Illustration
Key Words
cardiovascular risk
fibrosis
left ventricular mass regression
mineralocorticoid receptor antagonist
preserved ejection fraction
type 2 diabetes
Abbreviations and Acronyms
cLMM
constrained linear mixed model
CMR
cardiac magnetic resonance
CO
cardiac output
CVD
cardiovascular disease
EDV
end-diastolic volume
eGFR
estimated glomerular filtration rate
ESV
end-systolic volume
HF
heart failure
HFrEF
heart failure with reduced ejection fraction
LVEF
left ventricular ejection fraction
LVM
left ventricular mass
LVMi
left ventricular mass indexed
MI
myocardial infarction
MR
mineralocorticoid receptor
MRA
mineralocorticoid receptor antagonist
NT-proBNP
N-terminal pro–B-type natriuretic peptide
P1NP
procollagen type I N-terminal propeptide
P3NP
procollagen type III N-terminal propeptide
RAS-I
renin-angiotensin-system inhibitor
SV
stroke volume
uACR
urine-albumin-creatinine ratio
Cited by (0)
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2021 by the American College of Cardiology Foundation. Published by Elsevier.